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ABsTrACT
Translation of genomic alterations to protein changes 
in chronic obstructive pulmonary disease (COPD) is 
largely unexplored. Using integrated proteomic and RNA 
sequencing analysis of COPD and control lung tissues, 
we identified a protein signature in COPD characterised 
by extracellular matrix changes and a potential 
regulatory role for SUMO2. Furthermore, we identified 
61 differentially expressed novel, non- reference, peptides 
in COPD compared with control lungs. This included two 
peptides encoding for a new splice variant of SORBS1, 
of which the transcript usage was higher in COPD 
compared with control lungs. These explorative findings 
and integrative proteogenomic approach open new 
avenues to further unravel the pathology of COPD.
InTroduCTIon
Chronic obstructive pulmonary disease (COPD) 
has a high burden and rising mortality, with no 
curative treatment available. COPD is driven by 
a complex interaction between genetic and envi-
ronmental factors. Genome- wide association 
studies have shown that multiple single nucleotide 
polymorphisms are associated with COPD and 
have improved our insight into disease aetiology. 
The functional translation of these findings is an 
emerging field. In particular, the translation of 
genomic alterations to protein changes is impor-
tant, since proteins are the biologically active mole-
cules that reflect actual disease pathology. Hence, 
the vast majority of factors that contribute to the 
phenotypic profile of COPD initiation and progres-
sion lies within the proteome.
Proteomics is a rapidly developing area, also in 
the clinical setting, with, for example, the Cancer 
Moonshot initiative in precision oncology.1 
Mass spectrometry- based ‘shotgun’ proteomics 
is currently the most powerful, high- throughput 
technique enabling quantification and identifica-
tion of several tens of thousands of peptides and 
several thousands of proteins in complex biolog-
ical samples.2 3 Recently, this method proved to be 
successful in fibrotic lung and skin samples.4
MeThods
Here, we report on the first explorative study 
using an integrative proteogenomic approach to 
study pathogenetic changes in Stage IV COPD 
(n=10) compared with control (n=8) lung tissue 
(all ex- smokers, table 1). With this proteogenomics 
approach,5 we integrated mass spectrometry- based 
proteomic and RNA- sequencing data of polyade-
nylated transcripts of the same frozen lung tissue 
samples that were stored at −80°C, of which 
consecutive slides (10×10 µm) were cut and used 
for RNA and protein isolation (detailed methods 
in online supplementary files). The most important 
step in this integrated approach was the predic-
tion of the protein sequence variants present in 
each sample based on the RNA- sequencing data, 
creating sample- specific protein reference data-
bases. These protein reference databases were used 
for peptide and protein identification and quanti-
fication, allowing identification of patient- specific 
non- synonymous variants (including splice variants) 
and new transcript isoforms. Raw spectral counts 
(ie, number of peptide- spectrum match or PSMs) 
were calculated for (1) peptides uniquely mapping 
to Ensembl genes and (2) non- mapping, that is, 
non- reference, peptides based on the sample- 
specific protein reference databases. Proteomics 
and RNAseq data were normalised using upper 
quartile normalisation. The proteogenomics work-
flow and principal component analysis are shown in 
online supplementary figures S1 and S2 (data access 
via ArrayExpress E- MTAB-8251, scripts are avail-
able on request).
resulTs And dIsCussIon
This integrative approach resulted in the identi-
fication of 56 322 peptides, including 901 novel, 
non- reference peptides that would not have 
been identified without the RNAseq integration 
(figure 1A). These 56 322 peptides mapped to 1724 
proteins that were expressed with ≥3 PSMs in at 
least 5 patients with COPD or four controls. Among 
these 1724 proteins, we identified 177 upregu-
lated and 150 downregulated proteins in COPD 
compared with control lung tissue, with calumenin 
(CALU), synuclein gamma (SNCG) and hypoxia 
upregulated 1 (HYOU1) being the most significantly 
upregulated, and EH domain containing protein 
3 (EHD3), hexosaminidase subunit beta (HEXB) 
and erythrocyte membrane protein band 4.1 like 5 
(EPB41L5) being the most significantly downreg-
ulated proteins (false discovery rate (FDR)<0.05, 
figure 1B, online supplementary figure S3, online 
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Figure 1 (A) Venn diagram showing the total number of identified peptides that mapped to canonical sequences in the Uniprot and Ensembl public 
databases (normal text) and non- reference sequences (red bold text), which included non- synonymous variants (single amino acid variants), new 
transcript isoforms and confirmed gene models. (B) Volcano plot of all proteins consistently expressed in COPD and control lung tissue. Differentially 
expressed proteins (FDR<0.05) are in red. (C) STRING protein- protein interaction network based on differential protein expression in severe COPD 
using an FDR<0.01 cut off. Red connections show known protein- protein interactions from databases, grey connections represent experimentally- 
derived protein- protein interactions and blue connections are common database and experimentally derived interactions. Pie charts express the fold 
change at the transcript (left) and protein (right) level in severe COPD. The direction and fold change is indicated in blue (downregulated) and red 
(upregulated). The genes related to the extracellular matrix organisation gene ontology are highlighted in red. (D) Number of MS/MS spectra (PSMs) 
attributed to non- reference sample specific peptides that were exclusively identified in severe COPD and control lung tissue. Only peptides with at 
least five PSMs and present in at least four patients with COPD or controls were considered. The number of samples where the non- reference peptide 
was identified is indicated at the top of each bar. (E) Upper plot shows the genomic region of the new exon that was identified in the human SORBS1 
gene. The arrow indicates the location of an additional exon corresponding to 238 amino acid residues. SORBS1 is encoded on minus strand of chr10 
(band 10q24.1) between 95.31 and 95.56 Mbp (gene length: 249.64 kb). The lower plot shows the amino acid sequence of the new SORBS1 splice 
variant highlighting the additional novel exon (upper- case light- blue) and the two peptides identified by mass spectrometry (red). PSM, peptide- 
spectrum match.
supplementary table S1). Examples of four upregulated and 
four downregulated proteins, including the marginal zone B and 
B1 cell- specific protein (MZB1), are plotted in online supple-
mentary figure S4. MZB1 is a marker of IgG- producing plasma 
cells that was recently identified as upregulated in fibrotic lung 
tissue.4 Of the 327 differentially- expressed proteins, 37 showed 
differential transcript expression in the same direction, including 
MZB1 and several extracellular matrix (ECM) proteins (p<0.05, 
online supplementary figure S5). The volcano plot of the 226 
upregulated and 124 downregulated transcripts (FDR<0.05) is 
shown in online supplementary figure S6. Our transcript find-
ings were in high agreement with an independent lung tissue 
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Table 1 Clinical characteristics of patients with COPD and controls
Control CoPd stage IV
Number 8 10
Age, years 65 (7)* 58 (2)*
Sex (m/f) 4/4 2/8
Pack- years smoking 34 (17)† 40 (12)
FEV1%pred 95 (11)† 21 (4)
FEV1/FVC % 76 (4) 31 (10)
Mean (SD).
*P<0.05 control vs COPD.
†No information available w.r.t pack- years in one control and FEV1%pred in two 
controls.
FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
RNA- sequencing dataset (online supplementary figure S7).6
Enrichment analysis of differentially expressed proteins 
demonstrated enrichment of gene ontologies related to ECM and 
structure organisation (FDR p- value=1.05×10–4, online supple-
mentary table S2). The STRING protein interaction network 
based on differential protein expression indicated a central role 
for small ubiquitin- related modifier 2 (SUMO2) with 19 connec-
tions (figure 1C). Online supplementary figure S8 demonstrates 
higher connectivity of the edges in our proteomics dataset 
compared with the entire STRING database. SUMO2 belongs 
to the group of ubiquitin- like modifiers, which can target 
proteins in a similar manner to ubiquitination.7 8 Conjugation of 
SUMO2/3 to protein targets is induced by various stressors (eg, 
oxidative stress). As cells contain a large pool of unconjugated 
SUMO2/3,9 it has been proposed that one function of SUMO2/3 
is to provide a pool of free SUMO to respond to stress.7 Thus, 
the identification of SUMO2 may suggest a role in attenuating 
oxidative stress in COPD.
Of the 901 identified non- reference peptides, 17 and 9 were 
only identified in COPD and control lung tissue, respectively 
(figure 1D, online supplementary table S3). In addition, 35 non- 
reference peptides were differentially expressed between COPD 
and control (online supplementary figure S9). The majority of 
these peptides were single amino acid variants caused by non- 
synonymous variants (online supplementary table S4) and 10 
mapped to immunoglobulin proteins (online supplementary 
table S5), indicating changes in the specific immune response 
between COPD and control, which aligns with our previous 
observations10 and the changes in MZB1.
Interestingly, we identified two peptides that were only 
present in the COPD samples that mapped uniquely to an 
unknown splice variant of SORBS1 (sorbin and SH3 domain 
containing 1, figure 1E). SORBS1 is an adaptor protein involved 
in insulin signalling. Polymorphisms in the SORBS1 gene have 
been associated with various, non- lung related, diseases,11 12 but 
its role in lung disease is unexplored. The new SORBS1 splice 
variant includes an additional exon encoding for an atrophin-1 
domain. Atrophin-1 is a transcriptional regulator associated with 
the polyglutamine disease DRPLA (Dentatorubral- pallidoluysian 
atrophy).13 Nothing is known yet on the function of atrophin-1 
in lung; however, given its function as a transcriptional regulator, 
it is possibly affecting the transcription of SORBS1. Whereas 
these sequence variants were detected at the peptide level 
only in the COPD samples, transcripts were detected in both 
COPD and control samples. In an independent RNA- sequencing 
dataset (n=189),6 we demonstrated that the usage of this new 
exon for SORBS1 was significantly higher in COPD compared 
with control lung tissue (Mann- Whitney U test p=0.003, online 
supplementary figure S10).
The MS/MS spectra of the differentially expressed non- 
reference peptides (online supplementary file 1.6), the confirma-
tion of these findings using ion count label- free quantification 
(online supplementary figures S11 and S12) and confirmation 
with synthetic peptides (online supplementary file 1.7) is shown 
in the online supplementary file. Although COPD samples were 
derived from lung transplantation and control samples from 
tumour resection surgery, tissue sample processing and storage 
were similar. Although the (histologically normal) lung tissue was 
taken far from the tumour, a tumour effect cannot be excluded, 
but considering tumour heterogeneity, this would rather have 
precluded than induced positive findings.
ConClusIon
In summary, our protein signature in COPD confirmed impor-
tant ECM protein changes in COPD, identified SUMO2 as a 
potential regulatory protein, and resulted in the identification 
of a new splice variant of SORBS1. Although our study used 
a small, albeit homogenous, subset of samples from end- stage 
COPD, a comprehensive lung tissue protein signature was iden-
tified that was in part also apparent at the transcript level. Our 
study was hypothesis- generating and, given the small samples 
size, future studies are needed to further validate and extend our 
findings in a larger and independent cohort.
Taken together, our findings and our integrative approach 
provide promising new avenues to further unravel the molecular 
mechanisms of COPD pathology, which may have important 
implications for future patient care.
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